Tarsus Pharmaceuticals Stock Price To Sales
| TARS Stock | USD 49.91 0.36 0.73% |
Tarsus Pharmaceuticals fundamentals help investors to digest information that contributes to Tarsus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Tarsus Stock. The fundamental analysis module provides a way to measure Tarsus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tarsus Pharmaceuticals stock.
Tarsus |
Tarsus Pharmaceuticals Company Price To Sales Analysis
Tarsus Pharmaceuticals' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Tarsus Pharmaceuticals Price To Sales | 11.15 X |
Most of Tarsus Pharmaceuticals' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tarsus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Tarsus Pharmaceuticals has a Price To Sales of 11.1546 times. This is 47.88% lower than that of the Pharmaceuticals sector and 88.67% lower than that of the Health Care industry. The price to sales for all United States stocks is 2.32% higher than that of the company.
Tarsus Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tarsus Pharmaceuticals' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics of similar companies.Tarsus Pharmaceuticals is currently under evaluation in price to sales category among its peers.
Tarsus Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 1.82 B | ||||
| Shares Outstanding | 41.19 M | ||||
| Shares Owned By Insiders | 8.04 % | ||||
| Shares Owned By Institutions | 91.96 % | ||||
| Number Of Shares Shorted | 7.08 M | ||||
| Price To Book | 9.09 X | ||||
| Price To Sales | 11.15 X | ||||
| Revenue | 182.95 M | ||||
| Gross Profit | 116.74 M | ||||
| EBITDA | (106.88 M) | ||||
| Net Income | (115.55 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 72.45 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 5.86 X | ||||
| Cash Flow From Operations | (83.03 M) | ||||
| Short Ratio | 12.56 X | ||||
| Earnings Per Share | (3.07) X | ||||
| Price To Earnings To Growth | 0.28 X | ||||
| Target Price | 69.44 | ||||
| Number Of Employees | 323 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 2.04 B | ||||
| Total Asset | 376.99 M | ||||
| Retained Earnings | (360.21 M) | ||||
| Working Capital | 276.09 M | ||||
| Net Asset | 376.99 M |
About Tarsus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tarsus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.